In the CheckMate 227 Part 1 trial (NCT02477826), nivolumab with ipilimumab (anti-CTLA-4) was found to increase 5-year survival in patients with metastatic NSCLC compared to chemotherapy, although adverse events were increased [46,47]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.